Westover Capital Advisors LLC Sells 356 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Westover Capital Advisors LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,094 shares of the company’s stock after selling 356 shares during the period. Westover Capital Advisors LLC’s holdings in Medpace were worth $1,692,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Medpace by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company’s stock worth $66,794,000 after purchasing an additional 2,142 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in Medpace in the 4th quarter valued at $31,000. Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares during the last quarter. US Bancorp DE raised its position in Medpace by 1.7% in the 4th quarter. US Bancorp DE now owns 8,235 shares of the company’s stock valued at $2,736,000 after buying an additional 135 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in Medpace by 47.4% in the 4th quarter. Fisher Asset Management LLC now owns 183,353 shares of the company’s stock valued at $60,916,000 after buying an additional 58,954 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Price Performance

Shares of Medpace stock opened at $319.17 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The firm has a market cap of $9.72 billion, a PE ratio of 25.27, a P/E/G ratio of 3.81 and a beta of 1.36. The stock has a fifty day moving average price of $342.26 and a 200-day moving average price of $344.70.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.